Calidi Announces Reverse Stock Split, Expected to Begin Trading on a 1-for-16 Split Adjusted Basis on July 31, 2026
Calidi Biotherapeutics announced a 1-for-16 reverse stock split effective July 31, 2026, aimed at maintaining listing standards and optimizing market dynamics. The consolidation was approved by shareholders in June and the Board in mid-July, reducing every 16 pre-split shares to a single post-split share with a new CUSIP number.
Key figures
- Reverse split ratio
- 1-for-16
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.